CD274 and neoplasm: Furthermore, for patients whose tumor expresses the PDL-1 protein on at least 50% of the cells, the treatment options might include the administration of an immunotherapy drug, such as pembrolizumab, which is a human immune checkpoint inhibitor that can inhibit the PD-1 or PD-L1 and improve antitumor immunity [51,52,53].